Cabrera-Rayo A, Martínez-Zubieta R, Sobrevilla-Calvo P, Cantú-Brito C, Alcántar-Luna E, Vázquez-Delgado IM, Xibillé-Friedmann D

Language: Spanish
References: 22
Page: 29-33
PDF size: 48.30 Kb.

ABSTRACT

Most hospitalized patients have one or more risk factors to develop venous thromboembolic disease (VTD), an important cause of inhospital morbidity and mortality. Therefore, thromboprophylaxis must be indicated in all patients with risk factors. Low molecular weight heparins are the main drugs for pharmacological thromboprophylaxis. Possibility of VTD in hospitalized non-surgical patients is estimated by the level of risk associated (low, moderate, high and very high). In this section, some important recommendations are made for the prevention of VTD in hospitalized patients with non-surgical diseases. Antiphospholipid antibody syndrome is associated with both, venous and arterial thrombosis and adverse obstetric history. The relative risk of thrombosis is between 2 and 4 and the recurrence rises up to 18.7%/ year. Pregnancy and puerperium are thrombophilic states because they elevate the plasma concentration of hemostatic factors and the platelet count and diminish antithrombin and protein S plasma levels. Thromboprophylaxis is recommended in case of antecedent or current presence of VTD. Since estrogens raise the possibility of VTD each patient must be evaluated in terms of her thrombotic risk before starting this kind of therapy. Cancer patients represent 15 to 20% of total cases of VTD. Ten per cent of patients with idiopathic deep vein thrombosis (DVT) develop cancer in the following 12 to 24 months. Cancer represents a special thrombophilia associated to very specific prothrombotic risk factors. In intensive care units DVT reaches an 80% incidence because these patients have accumulative risk factors for VTD. Some general recommendations are done for different types of patients in these units. Patients with neurological diseases are also candidates for thromboprophylaxis. We suggest some thromboprophylactic strategies for the most common entities such as stroke and cerebral hemorrhage as well as for cerebral vein thrombosis.

REFERENCES

1. Huber O, Bournameaux H, Bourst F, Rohner A. Postoperative pulmonary embolism after hospital discharge. Arch Surg 1992;127:310-313.

2. Nicolaides AN, Breddin HK, Fareed J, Goldhaber S, Hass S, Hull R, et al. Cardiovascular Disease Educational and Research Trust and the International Union of Angiology. Prevention of venous thromboembolism. International Consensus Statement. Int Angiol 1997;16:3-38.

3. Holger J, Schünemann H, Munger H, Broker S, O¨Donnell M, Crowther M, et al. Methodology for guideline development for the Seventh American Collage of Chest Physicians conference on antithrombotic and thrombolytic therapy. Chest 2004;126:174S-178S.

4. Geerts WH, Pineo GF, Heit JA, Bergquist D, Lassen MR, Colwell CW, et al. Prevention of venous thromboembolism. Chest 2004;126:338S-400S.

5. Anand S, Wells P. Does this patient have deep vein thrombosis? JAMA 1998;279:1094-1099.

6. Wilson WA, Ghavari AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on preliminary classification criteria for definitive antiphospolipid syndrome: Report of an international workshop. Arthritis Rheum 1999;42:1309-1311.

7. Petri M. Epidemiology of the antiphospolipid syndrome. J Autoinmun 2000;15:145-151.

8. Crowther MA, Ginsberg JS, Julian J, Math M, Denburg J, Hish J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003;349:1133-1138.

9. Danilenko-Dixon DR, Heit JA, Silverstein MD, Yawn BP, Petterson TM, Lohse CM, et al. Risk factors for deep vein thrombosis and pulmonary embolism during pregnancy or postpartum. A population-based, case-control study. Am J Obstet Gynecol 2001;184:104-110.

10. Dilley A, Austin H, El-Jamil M, Hooper WC, Barnhart E, Evatt BL, et al. Genetic factors associated with thrombosis in pregnancy in a United Status population. Am J Obstet Gynecol 2000;183:1271-1277.

11. Carter C. Oral contraceptives and thrombosis. Curr Opin Pulm Med 2000;6:296-300.

12. Miller J, Benjamin KS, Heidi DN. Postmenopausal estrogen replacement and risk for venous thromboembolism: A systematic review and meta-analysis for de U.S. preventive services Task Force. Ann Intern Med 2002;136:680-690.

13. Asell JE. Air travel venous thromboembolism – is the evidence in? N Engl J Med 2001;345:828-829

14. Cesarone MR, Belcaro G, Nicolardes AN. Venous thrombosis from air travel: The LONFLIT3 study. Prevention with aspirin vs. low-molecular-weight heparin (LMWH)- in high-risk subjects: A randomized trial. Angiology 2002;53:1-6.

15. Lee AYY. Management of thrombosis in cancer: Primary prevention and secondary prophylaxis. Br J Haematol 2004;128:291-302.

16. Sorensen HT, Mellemkjaer L, Olsen JH, Olsen JH, Baron JA. Prognosis of cancer associated with venous thromboembolism New Engl J Med 2000;343:1846-1850.

17. Alikhan R, Cohen AT, Combe S, Samama M, Desjardins L, Eldor A, et al. Risk factors for venous thromboembolism in hospitalized patients with acute medical illnes: Analysis of the MEDENOX Study. Arch Intern Med 2004;164:963-968.

18. Lee AYY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M. Low-molecularweight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. New Engl J Med 2003;349:146-153.

19. Cook D, Crowther M, Meade M, Rabbat C, Griffith L, Schiff D, et al. Deep venous thrombosis in medical-surgery critically ill patients: Prevalence, incidence and risk factors. Crit Care Med 2005;33:1565-1571.

20. Evidence Based Guidelines Group American Burn Association. Deep venous thrombosis prophylaxis in burns. J Burn Care Rehabil 2001;22(suppl):67S-69S.

21. Hankey GJ. Low-molecular weight heparins or heparinoids versus standard non fractioned heparin for acute ischaemic stroke. Cochrane Corner. Stroke 2005;36:2045-2046.

22. Ferro JM, Canhao P, Stam J, Bousser JS, Barinagarrementeria F, for the ISCVT Investigators. Prognosis of cerebral vein and dural sinus thrombosis: Results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke 2004;35:664-670.